Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) – Analysts at B. Riley issued their FY2017 EPS estimates for Tetraphase Pharmaceuticals in a research note issued to investors on Monday. B. Riley analyst M. Kumar anticipates that the biopharmaceutical company will earn ($2.70) per share for the year. B. Riley currently has a “Buy” rating and a $11.00 target price on the stock. B. Riley also issued estimates for Tetraphase Pharmaceuticals’ FY2018 earnings at ($2.01) EPS.

TTPH has been the subject of several other research reports. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 12th. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, December 5th. ValuEngine cut shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, BidaskClub cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. Tetraphase Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $14.46.

Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at $5.43 on Wednesday. Tetraphase Pharmaceuticals has a 1-year low of $4.91 and a 1-year high of $9.93. The firm has a market cap of $265.71, a P/E ratio of -1.90 and a beta of 2.29.

Several institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its position in shares of Tetraphase Pharmaceuticals by 77.6% during the 4th quarter. Renaissance Technologies LLC now owns 592,493 shares of the biopharmaceutical company’s stock worth $3,733,000 after purchasing an additional 258,908 shares during the last quarter. AXA lifted its position in shares of Tetraphase Pharmaceuticals by 7.1% during the 4th quarter. AXA now owns 216,337 shares of the biopharmaceutical company’s stock worth $1,363,000 after purchasing an additional 14,400 shares during the last quarter. Virtus Fund Advisers LLC purchased a new stake in shares of Tetraphase Pharmaceuticals during the 4th quarter worth $376,000. BlackRock Inc. lifted its position in shares of Tetraphase Pharmaceuticals by 21.2% during the 4th quarter. BlackRock Inc. now owns 4,044,340 shares of the biopharmaceutical company’s stock worth $25,479,000 after purchasing an additional 707,296 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its position in shares of Tetraphase Pharmaceuticals by 28.5% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 505,000 shares of the biopharmaceutical company’s stock worth $3,182,000 after purchasing an additional 112,000 shares during the last quarter. 58.28% of the stock is owned by institutional investors and hedge funds.

In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 7,167 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total value of $44,507.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director L Patrick Gage acquired 3,880 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The shares were purchased at an average cost of $6.45 per share, with a total value of $25,026.00. Following the completion of the transaction, the director now owns 38,880 shares in the company, valued at approximately $250,776. The disclosure for this purchase can be found here. Company insiders own 5.50% of the company’s stock.

WARNING: “Equities Analysts Offer Predictions for Tetraphase Pharmaceuticals Inc’s FY2017 Earnings (TTPH)” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://theolympiareport.com/2018/02/14/equities-analysts-offer-predictions-for-tetraphase-pharmaceuticals-incs-fy2017-earnings-ttph.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.